Dr Stephen Kennedy | Radiation Oncologist | Icon Cancer Centre

Dr Stephen Kennedy

Radiation Oncologist
Become a Patient

Dr Stephen Kennedy has a deep commitment to clinical excellence and continuously improving patient experiences, outcomes and standards of care. His genuine care for his patients, high attention to detail, and clear communication ensures his patients feel well-informed, supported and confident they are in capable hands. 


Dr Stephen Kennedy is an experienced radiation oncologist at Icon Cancer Centre Midland and Icon Cancer Centre Rockingham. Dr Kennedy completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the Imperial College London in 2004. He received his specialist radiation oncology training at The Christie Hospital in Manchester (UK)– the largest single site cancer centre in Europe. He subsequently undertook a proton radiation therapy fellowship at MD Anderson Cancer in Texas (USA), and became a Fellow of the Royal College of Radiologists (FRCR) in 2014.

Prior to his arrival in Australia, Dr Kennedy spent nine years working as a radiation oncologist across The Christie National Health Service (NHS) Foundation Trust and Lancashire Teaching NHS Hospitals. He also held appointments as lead cancer clinician for Lancashire NHS Foundation Trust, senior manager at independent health advisory and delivery organisation Attain, board member of the Electronic Prescribing and Medicines Administration (EPMA) at the Lancashire Teaching Hospitals, and chair of The Christie Proton Immobilisation Group and Supra-Regional Stereotactic Radiosurgery meetings.

From 2018-2022, Dr Kennedy helped establish the inaugural United Kingdom NHS sarcoma proton radiation therapy service. He was responsible for developing and supervising complex treatment plans for patients with sarcoma and spinal tumours within a peer-review framework. He also co-led one of the UK’s busiest stereotactic radiation therapy services for brain tumours.

Dr Kennedy maintains a strong interest in clinical trials.  He was the principal investigator for the BR13, BR14 and HCQ trials and the Horizons observational study, was part of the ROAM trial steering committee, and contributed patients to many other oncology research studies. He also enjoys supporting oncology education. He was an educational supervisor for oncology specialist trainees and allied health professionals in the UK.  He also authored network cancer clinical guidelines, and audited services to enhance treatment protocols in line with the latest research evidence and guidelines. 

Dr Kennedy’s clinical experience covers a broad range of tumour malignancies. He has a special interest in lung cancer, brain and spine (CNS) cancer, genitourinary cancer, skin cancer, lymphoma, haematological malignancies and stereotactic radiation therapy.

Dr Kennedy enjoys sailing, hiking, nature and the outdoors. He is interested in his patient’s lives and considers their quality of life, survivorship, health and well-being, both during and beyond treatment.

Affiliations & Memberships

  • Fellow of Royal College of Radiologists (UK) 
  • British Institute of Radiology  
  • British Medical Association (BMA) 
  • European Society of Medical Oncology (ESMO) 
  • European Society for Radiotherapy and Oncology (ESTRO) 
  • Royal Australian and New Zealand College of Radiologists (RANZCR) 

Special Interests

Dr Stephen Kennedy accepts referrals for all cancer types, with a special clinical interest in:
  • Brain and spine (CNS) cancer
  • Genitourinary cancer
  • Lung cancer
  • Lymphoma
  • Skin cancer

Icon Locations

Midland View centre
Rockingham View centre


  • Li M, P Sitch, Lowe M, Appleyard H, Wylie J, Coyle C, Saunders D, Kennedy S. Improving proton treatment for spinal chordomas and chondrosarcomas: a comparison planning study between sequential boost and simultaneous integrated boost technique. Int J Part Ther. 2023; 9(4): 306–470. 

  • Frinton E, Tong D, Tan J, Read G, Kumar V, Kennedy S, Lim C, Board R. Metastatic melanoma: prognostic factors and survival in patients with brain metastases. J Neurooncol. 2017;135(3):507-512. 

  • Yim F, Howell L, Pan S, Kumar V, & Kennedy S. Outcomes of high grade glioma patients treated with two different radiotherapy regimes: The effect of prioritising tumour dose versus limiting dose to organs at risk. Neuroncol. 2017;19(suppl_1): i18. 

  • Hilton E, Marsden P, Thurston A, Kennedy S, Decalmer S, Smith JA. Clinical features of the urge-to-cough in patients with chronic cough. Respir Med. 2015;109(6):701-7.  

  • Whitfield GA, Kennedy SR, Djoukhadar IK, Jackson A. Imaging and target volume delineation in glioma. Clin Oncol. 2014;26(7):364-76.  

  • Kennedy S, Mahmood Q, Choudhury A, Livsey E. A Case of muscle invasive bladder cancer treated with systemic chemotherapy during pregnancy. J Clin Gynecol Obstet. 2012;1(1), 24-27.